A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours

Journal of Chemotherapy

Volumn 25, Issue 6, 2013, Pages 362-368

  Coker, Shodeinde A ^a   Dandamudi, Uday B ^a   Beelen, Andrew P ^a   Crosby, Nancy A ^a   Fisher, Jan L ^a   Obrocea, Michael ^b   Ernstoff, Marc S ^a   Lewis, Lionel D ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b Abbott Biotherapeutics Corp   (United States)

Author keywords

PEG IFN combination therapy; Phase I; Temozolomide

Indexed keywords

PEGINTERFERON ALPHA2B; TEMOZOLOMIDE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); SOLID TUMOR;

PEG-IFN COMBINATION THERAPY; PHASE I,; TEMOZOLOMIDE,;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84896726885     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947813Y.0000000102     Document Type: Article

References (25)

1. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987;47:5846-52.
2. Merck & Co. Inc. Temozolomide Product Label [document on the Internet]. Whitehouse Station (NJ): Merck & Co. Inc.; 2012 [cited 2012 Dec]. Available at: http://www.merck.com/product/usa/pi_circulars/t/temodar_capsules/temodar_pi.pdf
3. Friedman RM. Clinical uses of interferons. Br J Clin Pharmacol. 2008;65:158-62.
4. Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol. 2003;21:2551-7.
5. Garcia M, del Muro XG, Tres A, Crespo C, Valladares M, Lopez JJ, et al. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma. Melanoma Res. 2006;16:365-70.
6. Groves MD, Puduvalli VK, Gilbert MR, Levin VA, Conrad CA, Liu VH, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. Br J Cancer. 2009;101:615-20.
7. Merck & Co. Inc. Peginterferon Alfa-2b Product Label [document available on the Internet]. Whitehouse Station (NJ): Merck & Co. Inc.; 2012 [cited 2012 Dec]. Available at: http://www.merck.com/product/usa/pi_circulars/p/pegintron/pegintron_pi.pdf
8. Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis. 2003;23(Suppl 1):23-8.
9. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA. 1994;91:1198-205.
10. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem. 1998;67:227-64.
11. von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003;95:437-48.
12. Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, 3rd, Daud A, et al. Melanoma. J Natl Compr Canc Netw. 2012;10:366-400.
13. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-16.
14. Petrella T, Verma S, Spithoff K, Quirt I, McCready D; The Melanoma Disease Site Group. Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline. Clin Oncol (R Coll Radiol). 2012;24:413-23.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
16. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. 2000;68:556-67.
17. Gold Standard. Peginterferon Alfa-2b Monograph. Clin Pharmacol [database online]. 2012 [cited 2013 Apr]. Available at: http://www.clinicalpharmacology.com
18. Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology. 2000;32:647-53.
19. Gupta SK, Pittenger AL, Swan SK, Marbury TC, Tobillo E, Batra V, et al. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol. 2002;42:1109-15.
20. Wakabayashi T, Kayama T, Nishikawa R, Takahashi H, Hashimoto N, Takahashi J, et al. A multicenter phase I trial of combination therapy with interferon-beta and temozolomide for high-grade gliomas INTEGRA study): the final report. J Neurooncol. 2011 Sep;104:573-7.
21. Agarwala SS, Kirkwood JM. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study. Cancer. 2003 Jan 1;97:121-127.
22. Hwu WJ, Panageas KS, Menell JH, Lamb LA, Aird S, Krown SE, et al. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer. 2006 Jun 1;106:2445-51.
23. Spieth K, Kaufmann R, Dummer R, Garbe C, Becker JC, Hauschild A, et al. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Ann Oncol. 2008 Apr;19: 801-6.
24. Motomura K, Natsume A, Kishida Y, Higashi H, Kondo Y, Nakasu Y, et al. Benefits of interferon-beta and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: a multicenter study. Cancer. 2010 Nov 8.
25. Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M, et al. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res. 2005 Sep 1;65:7573-9.